| 19.77 -0.19 (-0.95%) | 12-08 15:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.07 | 1-year : | 28.11 |
| Resists | First : | 20.61 | Second : | 24.07 |
| Pivot price | 18.58  |
|||
| Supports | First : | 16.37 | Second : | 13.75 |
| MAs | MA(5) : | 19.34 |
MA(20) : | 18.2 |
| MA(100) : | 15.49 |
MA(250) : | 0 | |
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 84 |
D(3) : | 81.4 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 24.34 | Low : | 10.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DNLI ] has closed below upper band by 20.6%. Bollinger Bands are 47.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 20.63 - 20.75 | 20.75 - 20.86 |
| Low: | 19.67 - 19.8 | 19.8 - 19.91 |
| Close: | 19.78 - 19.98 | 19.98 - 20.16 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Sun, 07 Dec 2025
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Sun, 07 Dec 2025
Will Denali Therapeutics' (DNLI) US$275 Million Tividenofusp Royalty Deal Change Its Investment Narrative? - simplywall.st
Sat, 06 Dec 2025
Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance
Sat, 06 Dec 2025
3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank - MarketBeat
Fri, 05 Dec 2025
What's Going On With Denali Therapeutics Stock Friday? - Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Fri, 05 Dec 2025
BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 147 (M) |
| Shares Float | 133 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 101.3 (%) |
| Shares Short | 14,020 (K) |
| Shares Short P.Month | 14,530 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -44.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.87 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -398 (M) |
| Levered Free Cash Flow | -250 (M) |
| PE Ratio | -6.79 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|